Home >> Expert Review of Cardiovascular Therapy, Volume 4, Number 4

Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

Authors: Pfützner, Andreas; Schneider, Christian A; Forst, Thomas

Source: Expert Review of Cardiovascular Therapy, Volume 4, Number 4, July 2006 , pp. 445-459(15)

Publisher: Expert Reviews

Buy & download fulltext article:

OR

Price: $73.00 plus tax (Refund Policy)

Abstract:

The antidiabetic compound pioglitazone, an activator of the intracellular peroxisome proliferator-activated receptor-γ, and decreases metabolic and vascular insulin resistance. The drug is well tolerated, and its metabolic effects include improvements in blood glucose and lipid control. Vascular effects consist of improvements in endothelial function and hypertension, and a reduction in surrogate markers of artherosclerosis. In a large, placebo-controlled, outcome study in secondary prevention, PROactive study, the use of pioglitazone in addition to an existing optimized macrovascular risk management resulted in a significant reduction of macrovascular endpoints within a short observation period that was comparable to the effect of statins and angiotensin converting enzyme inhibitors in other trials. These results underline the value of pioglitazone for managing the increased cardiovascular risk of patients with a metabolic syndrome or Type 2 diabetes mellitus.
More about this publication?
Related content
Marked list

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
^ Back to top
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page